• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Teva Pharmaceutical Industries Limited

    4/9/25 4:12:16 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TEVA alert in real time by email
    DEFA14A 1 d938758ddefa14a.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐    Preliminary Proxy Statement    ☐    Confidential, For Use of the Commission
    Only (as permitted by Rule 14a-6(e)(2))
    ☐    Definitive Proxy Statement
    ☒    Definitive Additional Materials      
    ☐    Soliciting Material under §240.14a-12      

    TEVA PHARMACEUTICAL INDUSTRIES LIMITED

    (Name of Registrant as Specified In Its Charter)

     

        

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

     

    ☒    No fee required.
    ☐    Fee paid previously with preliminary materials.
    ☐    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     


    LOGO

    MMMMMMMMMMMM Teva Pharmaceutical C 1234567890 Industries Limited ENDORSEMENT_LINE SACKPACK MMMMMMM MR A SAMPLE Online DESIGNATION (IF ANY) Go to www.investorvote.com/teva or scan ADD 1 000001 ADD 2 the QR code — login details are located in the ADD 3 shaded bar below. ADD 4 MMMMMMMMM ADD 5 ADD 6 Votes submitted electronically must be received by 8 a.m., Eastern Time, on June 3, 2025. Teva Pharmaceutical Industries Limited Shareholder Meeting Notice 1234 5678 9012 345 Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to be Held on June 5, 2025 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual shareholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This is not a votable ballot. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The notice of annual meeting of shareholders and proxy statement and annual report to shareholders are available at: www.investorvote.com/teva Easy Online Access — View your proxy materials and vote. Step 1: Go to www.investorvote.com/teva. Step 2: Click on the icon on the right to view meeting materials. Step 3: Return to the investorvote.com window and follow the instructions on the screen to log in. Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Obtaining a copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before May 15, 2025 to facilitate timely delivery. Unless requested, you will not otherwise receive a paper or email copy.


    LOGO

    Shareholder Meeting Notice Teva Pharmaceutical Industries Limited’s Annual Meeting of Shareholders to be held on Thursday, June 5, 2025 at 4:00 p.m. (local time), 9:00 a.m. (Eastern time), in a virtual format only (the “Annual Meeting”). Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. Teva’s Board of Directors recommends that you vote FOR Proposals 1A, 1B, 1C, 1D, 1E, 2, 3, 4, 5A, 5B and 6. . Election of DirectorsA. Chen Lichtenstein—to serve until Teva’s 2027 Annual MeetingB. Amir Elstein—to serve until Teva’s 2028 Annual MeetingC. Roberto A. Mignone—to serve until Teva’s 2028 Annual Meeting D. Dr. Perry D. Nisen to serve until Teva’s 2028 Annual Meeting E. Dr. Tal Zaks to serve until Teva’s 2028 Annual Meeting 2. To approve, on a non-binding advisory basis, the compensation for Teva’s named executive officers 3. To approve an amended compensation policy with respect to the terms of office and employment of Teva’s executive officers and directors* 4. To approve an amendment to the terms of office and employment of Teva’s president and chief executive officer 5. To approve an amendment to Teva’s Director Compensation A. To approve the compensation to be provided to Teva’s non-employee directors B. To approve the compensation to be provided to Teva’s non-executive chairman of the board 6. To appoint, Kesselman & Kesselman, a member of PriceWaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2026 annual meeting of shareholders In addition, shareholders will consider Teva’s annual consolidated financial statements for the year ended December 31, 2024. *By voting in accordance with the instructions provided herein, the voter will certify that it is NOT a “controlling shareholder” of Teva and does not have a personal benefit or other personal interest in Proposal 3, unless it notifies otherwise the Company at [email protected] by no later than 8:00 a.m., Eastern time, on June 3, 2025. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to vote at the Annual Meeting through the online meeting platform, you must present your Teva ADSs for cancellation and withdrawal of the corresponding Teva ordinary shares in time to be a shareholder of Teva as of the record date on April 14, 2025. PLEASE NOTE: In order for your ADS votes to be counted, you must be an ADS holder as of April 14, 2025. Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.investorvote.com/teva. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to [email protected] with “Proxy Materials Teva Pharmaceutical Industries Limited” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, requests for a paper copy of proxy materials must be received by May 15, 2025.


    LOGO

    Your Vote Counts!TEVA PHARMACEUTICAL INDUSTRIES LIMITED2025 Annual MeetingVote by June 02, 2025 11:59 PM ETHextone, Inc.P.O. Box 91421 Farmingdale, NY 11735 148,294 322,224 OF2 Ricky Campana P.O. Box 123456Suite 500 30#51 Mercedes Way Edgewood, NY 11717FLASHID-JOB#You invested in TEVA PHARMACEUTICAL INDUSTRIES LIMITED and it’s time to vote!You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on June 05, 2025. Get informed before you voteView the Proxy Statement, Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 15, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.For complete information and to vote, visit www.ProxyVote.com Control # XXXX XXXX XXXX XXXXSmartphone users Vote in Person at the Meeting*Point your camera here and June 05, 2025 vote without entering a 9:00 AM EST control number Virtual938758-001 09Apr25 11:35 Page 4 *If you choose to vote these shares in person at the meeting, you must request a “legal proxy.” To do so, please follow the instructions at www.ProxyVote.com or request a paper copy of the materials, which will contain the appropriate instructions. Please check the meeting materials for any special requirements for meeting attendance.


    LOGO

    Vote at www.ProxyVote.com Control # XXXX XXXX XXXX XXXXTHIS IS NOT A VOTABLE BALLOT TEVA PHARMACEUTICAL INDUSTRIES LIMITED 2025 Annual MeetingThis is an overview of the proposals being presented at the Vote by June 02, 2025 upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. 11:59 PM ETVoting Items Board Recommends1. Election of DirectorsNominees:1A Chen Lichtenstein For1B Amir Elstein For1C Roberto A. Mignone For1D Dr. Perry D. Nisen For1E Dr. Tal Zaks For2 To approve, on a non-binding advisory basis, the compensation for Teva’s named Executive Officers For3 To approve an amended compensation policy with respect to the terms of office and employment of Teva’s ForExecutive Officers and Directors4 To approve an amendment to the terms of office and employment of Teva’s President and Chief Executive Officer For5A To approve the compensation to be provided to Teva’s Non-Employee Directors For5B To approve the compensation to be provided to Teva’s Non-Executive Chairman of the Board For6 To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited, as Teva’s For independent registered public accounting firm until Teva’s 2026 Annual Meeting of ShareholdersNOTE: IMPORTANT NOTE: By executing this proxy card, the undersigned is confirming that the undersigned is NOT a “controlling shareholder” of Teva and does not have a personal benefit or other interest in Proposal 3. If you have such a personal benefit or other interest in Proposal 3, please notify the Company at [email protected] by no later than 4:00 p.m., Israeli time on June 3, 2025. See the Proxy Statement for more information, including the definitions of “controlling shareholders” under the Israeli Companies Law. The Company is not currently aware of any “controlling shareholder,” as defined under the Israeli Companies Law. In addition, Teva believes that the vast majority of its shareholders should not have a personal benefit or other personal interests in Proposal 3. This proxy card, when properly executed, will be voted in the matter directed herein by the undersigned. Any and all proxies heretofore given are hereby revoked.Under New York Stock Exchange rules, brokers may vote “routine” matters at their discretion if your voting instructions are not communicated to us at least 10 days before the meeting. We will nevertheless follow your instructions, even if the broker’s discretionary vote has already been given, provided your instructions are received prior to the meeting date.938758-001 09Apr25 11:35 Page 5 1.00000 322,224FLASHID-JOB# 148,294


    The following communication was sent to certain holders of the ordinary shares of the Company:

     

    LOGO  

    TEVA PHARMACEUTICAL INDUSTRIES LIMITED

     

    2025 ANNUAL MEETING OF SHAREHOLDERS

    June 5, 2025

    4:00 p.m. (Israel time), 9:00 a.m. (Eastern time)

    Virtual format only

     

    Participation instructions for the Teva Pharmaceutical Industries Limited
    2025 Annual Meeting of Shareholders and information on how to vote through the
    online meeting platform are available in the proxy statement which can be viewed at
    www.tevapharm.com/2025proxymaterials.

    Important Notice Regarding the Availability of Proxy Materials for the

    Shareholder Meeting to be Held on June 5, 2025.

    Notice is hereby given that the 2025 Annual Meeting of Shareholders (the “meeting”) of Teva Pharmaceutical Industries Limited (“Teva”) will be held in a virtual format on June 5, 2025 at 4:00 p.m. (Israel time) / 9:00 a.m. (Eastern time).

    This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. This is not a form for voting.

    The Notice of Annual Meeting of Shareholders and Proxy Statement and Annual Report are available at www.tevapharm.com/2025proxymaterials.

    If you want to receive a paper copy or an e-mail with links to the electronic materials, you must request one. There is no charge to you for requesting a copy. Please make your request for a copy as instructed below on or before May 15, 2025 to facilitate timely delivery. Unless requested, you will not otherwise receive a paper or email copy.

    Matters intended to be acted upon at the meeting are listed below.

     

    1.

    To appoint the following persons to Teva’s Board of Directors: Chen Lichtenstein to serve as a director until Teva’s 2027 annual meeting of shareholders, and Amir Elstein, Roberto A. Mignone, Dr. Perry Nisen and Dr. Tal Zaks to serve as directors until Teva’s 2028 annual meeting of shareholders.

     

    2.

    To approve, on a non-binding advisory basis, the compensation for Teva’s named executive officers.

     

    3.

    To approve Teva’s amended Compensation Policy with respect to the terms of office and employment of Teva’s executive officers and Directors.

     

    4.

    To approve an amendment to the terms of office and employment of Teva’s President and Chief Executive Officer.

     

    5.

    Approval of an amendment to Director compensation:

     

      5.1.

    To approve an amendment to the compensation to be provided to Teva’s non-employee Directors.

     

      5.2.

    To approve an amendment to the compensation to be provided to Teva’s non-executive Chairman of the Board.

     

    6.

    To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2026 annual meeting of shareholders.

    In addition, shareholders will consider Teva’s annual consolidated financial statements for the year ended December 31, 2024.

    The Board of Directors recommends that you vote FOR all proposals.


    To request paper copies of the proxy materials, which include the proxy card,

    proxy statement and annual report, please contact us via:

     

      •  

    Telephone – Call our proxy solicitor, Innisfree M&A, Inc., toll free within the U.S. and Canada at +1 (877) 825-8964 or outside the U.S. at + 1 (412) 232-3651. In Israel, call us at +972 (3) 914-8262.

     

      •  

    Email – Send us an email at [email protected]. The email must include:

     

      •  

    Your preference to receive printed materials via mail -or- to receive an email with links to the electronic materials.

     

      •  

    If you choose email delivery you must include the email address.

     

      •  

    If you would like this election to apply to delivery of material for all future meetings, write the word “Permanent”.

    In order to ensure timely delivery, you must request the information no later than May 15, 2025.

     

    2

    Get the next $TEVA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TEVA

    DatePrice TargetRatingAnalyst
    6/6/2025$24.00Buy
    Goldman
    5/28/2025$25.00Buy
    Truist
    5/12/2025$23.00Neutral → Overweight
    Analyst
    7/10/2024$20.00Hold → Buy
    Argus
    3/8/2024$14.00Underweight → Neutral
    JP Morgan
    2/12/2024$12.00 → $19.00Neutral → Overweight
    Piper Sandler
    1/23/2024$10.00 → $14.00Hold → Buy
    Jefferies
    1/3/2024$8.00 → $12.00Underweight → Neutral
    Piper Sandler
    More analyst ratings

    $TEVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Teva Pharma with a new price target

      Goldman initiated coverage of Teva Pharma with a rating of Buy and set a new price target of $24.00

      6/6/25 8:33:51 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Truist initiated coverage on Teva Pharma with a new price target

      Truist initiated coverage of Teva Pharma with a rating of Buy and set a new price target of $25.00

      5/28/25 9:09:46 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva Pharma upgraded by Analyst with a new price target

      Analyst upgraded Teva Pharma from Neutral to Overweight and set a new price target of $23.00

      5/12/25 8:18:58 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    SEC Filings

    See more
    • SEC Form 8-K filed by Teva Pharmaceutical Industries Limited

      8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)

      6/5/25 4:52:32 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by Teva Pharmaceutical Industries Limited

      SD - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)

      6/2/25 4:06:38 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva Pharmaceutical Industries Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

      8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)

      5/28/25 4:11:41 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Teva Releases Q2 2025 Aide Memoire

      TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the "Investors" page on its website. Q2 2025 Aide Memoire Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicine

      6/26/25 4:30:00 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

      6/26/25 11:44:00 AM ET
      $ADCT
      $CTOR
      $ONCY
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

      TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial results on Wednesday, July 30, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be available within 24 h

      6/25/25 4:30:00 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Financial Officer Kalif Eliyahu Sharon sold $952,464 worth of Ordinary Shares (55,775 units at $17.08), decreasing direct ownership by 12% to 403,288 units (SEC Form 4)

      4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

      6/16/25 4:03:30 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Vergis Janet S. converted options into 9,632 units of Ordinary Shares, increasing direct ownership by 15% to 73,697 units (SEC Form 4)

      4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

      6/9/25 4:25:12 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Zaks Tal Zvi converted options into 9,632 units of Ordinary Shares, increasing direct ownership by 20% to 58,772 units (SEC Form 4)

      4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

      6/9/25 4:22:54 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    Leadership Updates

    Live Leadership Updates

    See more
    • The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

      6/26/25 11:44:00 AM ET
      $ADCT
      $CTOR
      $ONCY
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations

      Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company's manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is leaving after 11 years with the Company, including more than four years as Executive Vice President, Global Operations. Mr. Shields will be a member of Teva's Executive Leadership Team and report directly to President and CEO Richard Francis. He will be based in Teva's U.S. headquarters in Parsippany, NJ. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2

      5/15/24 8:15:00 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business

      Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api). Dr. Ananth will lead the API business starting November 27, 2023, and will be based out of Teva's U.S. headquarters in Parsippany, NJ. Richard Francis, Teva's President and CEO said: "I am excited to welcome Ananth back to Teva to lead the Teva api business during this pivotal time for our company, as we continue to progress on our plan for turning Teva api into a standalone business. We're confident that this strategy will result in a more focused end-to-end operation, and I am confident tha

      11/7/23 4:30:00 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    Financials

    Live finance-specific insights

    See more
    • Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

      TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial results on Wednesday, July 30, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be available within 24 h

      6/25/25 4:30:00 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved

      For an accessible version of this Press Release, please visit www.tevapharm.com On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues recorded for Sanofi collaboration.Q1 2025 revenues of $3.9 billion, an increase of 5%; net of $100 million foreign exchange impact, reported revenues growth of 2%.AUSTEDO® – shows continued strong growth, with worldwide revenues of $411 million in Q1 2025, an increase of 39% in local currency terms compared to Q1 2024; increasing 2025 full-year revenue outlook from ~$1.9-2.05 billion to $1.95-2.05 billion.AJOVY® – global revenues of $139 million

      5/7/25 7:00:00 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City

      TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host Innovation & Strategy Day on Thursday, May 29, 2025 to discuss the acceleration phase of its strategy and portfolio priorities. The event will take place in New York, N.Y. Presentations will begin at 8:30 a.m. Eastern Time and are expected to conclude at 12:30 p.m. Eastern Time. Richard Francis, Teva's President and CEO, along with other members of the executive management team will discuss an update on the strategy and key priorities focusing on growth and innovation. Due to limited capacity, in-person attendance is by invitation only. Analysts a

      5/7/25 7:00:00 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

      SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

      11/12/24 10:34:14 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Teva Pharmaceutical Industries Limited (Amendment)

      SC 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

      4/9/24 10:26:26 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

      SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

      2/1/24 8:03:56 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care